1.
Hematol Oncol Clin North Am
; 36(6): 1077-1095, 2022 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36400532
RESUMO
One of the challenges in sickle cell disease is its clinical variability. Our ability to identify the complications that a patient is at risk for is limited by a lack of validated diagnostic and prognostic biomarkers. Clinical care is limited by a lack of diagnostics to capture the biological variability needed to precisely direct patient care. Many biomarkers have been proposed, but few validated. We must make a concerted effort as a field to rigorously test proposed biomarkers to improve outcomes for our patients.